12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Esbriet pirfenidone regulatory update

Health Canada approved Esbriet pirfenidone from InterMune to treat mild to moderate idiopathic pulmonary fibrosis (IPF) in adults. InterMune plans to launch the drug in Canada on Jan. 1, 2013. InterMune said it expects to secure insurance coverage of Esbriet from "some" private...

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >